(6aR,9R,10aR)-7-isopentyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-carboxylic acid | 60946-61-4

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 麦角林及其衍生物
• 英文名称: (6aR,9R,10aR)-7-isopentyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-carboxylic acid
• CAS: 60946-61-4
• 化学式: C₂₀H₂₆N₂O₂
• 分子量: 326.439
• InChiKey: ZLSZUNHQFDVAOB-QGPMSJSTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.63
• 重原子数：
  24.0
• 可旋转键数：
  4.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  56.33
• 氢给体数：
  2.0
• 氢受体数：
  2.0

反应信息

• 作为反应物：
  描述：

  甲醇 、 (6aR,9R,10aR)-7-isopentyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-carboxylic acid 在 硫酸 作用下， 生成
  参考文献：
  名称：

  Ergoline derivatives as highly potent and selective antagonists at the somatostatin sst1 receptor

  摘要：

  Non-peptidic compounds containing the octahydro-indolo[4,3-fg]quinoline (ergoline) structural element have been optimized into derivatives with high affinity (pK(d) r sst(1) > 9) and selectivity (> 1000-fold for h sst(1) over h sst(2)-h sst(5)) for the somatostatin sst(1) receptor. In functional assays, these ergolines act as antagonists at human recombinant sst(1) receptors. Pharmacokinetic studies in rodents reveal good oral bioavailability and brain penetration for some of these compounds. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.12.030
• 作为产物：
  描述：

  在 palladium on activated charcoal 氢气 作用下， 生成 (6aR,9R,10aR)-7-isopentyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-carboxylic acid
  参考文献：
  名称：

  Ergoline derivatives as highly potent and selective antagonists at the somatostatin sst1 receptor

  摘要：

  Non-peptidic compounds containing the octahydro-indolo[4,3-fg]quinoline (ergoline) structural element have been optimized into derivatives with high affinity (pK(d) r sst(1) > 9) and selectivity (> 1000-fold for h sst(1) over h sst(2)-h sst(5)) for the somatostatin sst(1) receptor. In functional assays, these ergolines act as antagonists at human recombinant sst(1) receptors. Pharmacokinetic studies in rodents reveal good oral bioavailability and brain penetration for some of these compounds. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.12.030